Loading…
Employees: 371
Size Phathom Pharmaceuticals (PHAT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $427M, the 2807th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.25 on 6 Nov 2026.
Performance Over six months the shares fell 56.8%, against -13.2% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 86.8% over the last twelve months (peer median +3.1%); the operating margin is -9.3% (peer median 5.0%).
Valuation It trades at 24.2× forward earnings against a peer median of 20.0× (3rd most expensive of 9).
Capital Return on invested capital runs 93.2 points below its cost of capital (6.7% WACC).
Short interest Short interest is 12.1% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $275M | $175M | $55.3M | $682,000 | $0 |
| Revenue growth | — | +217% | +8,001% | — | — |
| Gross profit | $222M | $153M | $47.3M | -$60,000 | -$620,000 |
| EBITDA | -$25.0M | -$159M | -$277M | -$167M | -$172M |
| Net income | -$83.0M | -$221M | -$334M | -$202M | -$198M |
| Free cash flow | -$21.0M | -$167M | -$267M | -$139M | -$148M |
| Capital expenditure | $302,000 | $229,000 | $135,000 | $1.63M | $1.04M |
| Total debt | $555M | $589M | $555M | $446M | $214M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHAT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.4% | -11.7% | lowest of 21 |
| 6-month return | -56.8% | -13.2% | lowest of 20 |
| Distance from 52-week high | -71.3% | -33.9% | lowest of 21 |
| Revenue growth (TTM) | +86.8% | +3.1% | 3rd highest of 19 |
| Operating margin | -9.3% | 5.0% | 6th lowest of 19 |
| Forward P/E | 24.2× | 20.0× | 3rd most expensive of 9 |
| ROIC minus cost of capital | -93.2 pp | -0.9 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 24.2× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 21.7× | 2.8% | +0.3% |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | n/a | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 7.6× | -8.8% | +12.8% |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 21.2× | 9.9% | +6.7% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 18.9× | 19.7% | +3.5% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | n/a | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | n/a | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 54.8× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 14.4× | -4.5% | +12.1% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | n/a | -0.4% | +11.2% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | n/a | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 6.2× | -16.9% | +7.2% |